INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, open-label, multi-cohort, exploratory phase II clinical trial in
patients with either CEACAM5-positive NSQ NSCLC, ER+ breast cancer or gastric cancer.
Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). The investigators
hypothesize that intratumoral exposure of Tusamitamab ravtansine would be an important factor
in determining treatment efficacy. Combining exposure with measurements of tumor PD reactions
in a proper PK/PD study is the goal of this study.